Image guided dose escalated prostate radiotherapy: still room to improve

[1]  C. Ménard,et al.  Image guided dose escalated prostate radiotherapy: still room to improve , 2009, Radiation Oncology (London, England).

[2]  J. Lebesque,et al.  Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[3]  Andrew Bayley,et al.  Inter-professional variability in the assignment and recording of acute toxicity grade using the RTOG system during prostate radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Weiguo Lu,et al.  Correlation between dosimetric effect and intrafraction motion during prostate treatments delivered with helical tomotherapy , 2008, Physics in medicine and biology.

[5]  J. Lebesque,et al.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[6]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Liying Zhang,et al.  Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. , 2008, International journal of radiation oncology, biology, physics.

[8]  Timothy D. Solberg,et al.  Dosimetric consequences of intrafraction prostate motion. , 2008, International journal of radiation oncology, biology, physics.

[9]  Y. Yamada,et al.  Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. , 2008, European urology.

[10]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[11]  M. Yassa,et al.  Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  Patrick A Kupelian,et al.  Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[13]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[14]  A. Zietman.  Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. , 2008, JAMA.

[15]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jan J W Lagendijk,et al.  Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. , 2007, International journal of radiation oncology, biology, physics.

[17]  Lei Dong,et al.  Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[18]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[19]  M. Kattan,et al.  Nomograms for prostate cancer , 2006, BJU international.

[20]  P. Warde,et al.  Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. , 2006, The Canadian journal of urology.

[21]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[22]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[23]  Radhe Mohan,et al.  Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[24]  R. Bristow,et al.  A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Markus Graefen,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update , 2004, Aktuelle Urologie.

[26]  Patrick A. Kupelian,et al.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. , 2007, International journal of radiation oncology, biology, physics.

[27]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[28]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[29]  J. Lagendijk,et al.  Partial boosting of prostate tumours. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[31]  L Souhami,et al.  Controversies in prostate cancer radiotherapy: consensus development. , 2001, The Canadian journal of urology.

[32]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[33]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[34]  J. Crook,et al.  Prostate motion during standard radiotherapy as assessed by fiducial markers. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  V. Fonteyne,et al.  Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. , 2009, International journal of radiation oncology, biology, physics.

[36]  M. Eisenberger.  Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven , 2009 .

[37]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[38]  Patrick A Kupelian,et al.  Image-guided radiotherapy for localized prostate cancer: treating a moving target. , 2008, Seminars in radiation oncology.

[39]  H. Sandler,et al.  Hormone therapy and radiotherapy for intermediate risk prostate cancer. , 2008, Seminars in radiation oncology.

[40]  C. C. Parkera,et al.  Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration , 2003 .

[41]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .